Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database
- 1 February 2018
- journal article
- review article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 47 (4) , 485-491
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?Annals of the Rheumatic Diseases, 2014
- Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?Clinical Therapeutics, 2013
- Mecanismo de acción de abatacept: concordancia con su perfil clínicoReumatología Clínica, 2012
- Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationJournal of Medical Economics, 2012
- Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims dataRheumatology International, 2011
- Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysisArthritis Research & Therapy, 2011
- Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskeletal Disorders, 2011
- Indirect comparison of biological treatments in refractory rheumatoid arthritisJournal of Clinical Pharmacy and Therapeutics, 2011
- Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countriesMedical Science Monitor, 2011
- Anti-TNF- therapies: they are all the same (aren't they?)Rheumatology, 2004